|
16.12.2011
Gunter Meister is investigating whether microRNAs could be used to eliminate dangerous dormant cancer stem cells. The biochemist is a professor at the Institute of Biochemistry, Genetics and Microbiology at the University of Regensburg.
|
|
26.10.2011
Cordian Beyer, a researcher at its Institute of Neuroanatomy at the RWTH Aachen is researching a hormone therapy for stroke and multiple sclerosis patients.
|
|
15.10.2011
Christoph Kaleta’s work is about understanding the metabolic processes that take place in organisms. The just 28 year-old systems biologist in Jena has the big picture in mind.
|
|
23.09.2011
Alexander Knoll is the founder of the Berlin-based biotechnology company BioGenes. After a turbulent beginning for his firm in the post-wall era, BioGenes is now on the path towards world market leadership in quality assurance assays.
|
|
25.08.2011
The proteins in cell walls and membranes run like a red thread through Dirk Linke’s research career. The scientist at the Max Planck Institute for Developmental Biology in Tübingen is investigating structures found on the surfaces of related bacteria. The work is part of a targeted search for new vaccines.
|
|
02.08.2011
Axel Ullrich is a pioneer in cancer research, as well as the founder of four different biotechnology companies. The research work by the Head of the Department of Molecular Biology at the Max Planck Institute for Biochemistry has resulted in four approved cancer drugs.
|
|
21.06.2011
Thomas Eschenhagen is reconstructing the heart in order to understand it in detail. The heart specialist is also spokesperson for the new German Center for Cardiovascular Research.
|
|
24.05.2011
Julia Bandow at the Ruhr University in Bochum is hunting for antibiotics with novel modes of action. In her work, the junior professor can call on her years of research experience at a US pharmaceutical giant.
|
|
06.04.2011
The molecular biologist Gülsah Gabriel is tracking down of the amazing adaptability of flu viruses. At the Heinrich Pette Institute in Hamburg, she is working on obstructing the pathogens' path in the nuclei of the host cells.
|
|
08.03.2011
With his penchant for Gustav Mahler, Peter Pohl nearly ended up in cultural management instead of biotechnology. He entered the family business 14 years ago, and today Pohl is President of GATC Biotech AG and an expert on DNA sequencing.
|
